<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>jmedicalcasereports</PublisherName>
      <JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
      <PISSN>I</PISSN>
      <EISSN>S</EISSN>
      <Volume-Issue>Volume 1; Issue 4</Volume-Issue>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season>(Jul-Aug, 2020)</Season>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>-0001</Year>
        <Month>11</Month>
        <Day>30</Day>
      </PubDate>
      <ArticleType>Medical Case Reports</ArticleType>
      <ArticleTitle>Catheter-Related Infection (CRI) Treatment with Taurolidine - Citrate Lock Solution in Patients Undergoing Total Parenteral Nutrition</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>1</FirstPage>
      <LastPage>6</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Dario</FirstName>
          <LastName>Tammaro</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Maria Teresa Di</FirstName>
          <LastName>Dato</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Gennaro</FirstName>
          <LastName>Liguori</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Giuseppina</FirstName>
          <LastName>Scicchitano</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Anna Maria</FirstName>
          <LastName>Salzano</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Elisabetta</FirstName>
          <LastName>Saracco</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Pietro</FirstName>
          <LastName>Buonavolontà</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Alfonso</FirstName>
          <LastName>Papa</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI/>
      <Abstract>The use of central venous catheter (CVC) is associated with risk of catheter-related infection (CRI). They have a huge impact on healthcare costs. One of the prevention strategies of CRI is the administration of non-antibiotic lock solutions such as taurolidine. Taurolidine has been proposed as a lock therapy in CVC because of its antimicrobial effect against a broad range of microrganisms. Some authors suggest a beneficial role of taurolidine lock solution application not only for prevention of CRI but for CRI therapy too. In this paper we report six cases of patient undergoing TPN with CRI treated with taurolidine 1.35 % - citrate 4% (TC), implanted in Department of Pain Therapy - Vascular Access Device Ambulatory, (Monaldi Hospital, Naples - Italy). Patients were in Total Parenteral Nutrition (TPN) and received central (CBC) and peripheral blood culture (PBC), clinical evalutation, white blood cell (WBC) count. Patients with positive blood culture received TC every 48 hours throughout vascular access. Parenteral nutrition was suspended only during the day of TC infusion. The drug was administered until the patients didn’t show no fever. In our experience, TC eradicated CRI in all six patients in a six-days therapy, interrupting the TPN only for three days. No side effects occurred. The efficacy of TC in this series of case reports has made possible to resolve all CRI with simple outpatient treatments and therefore could be a further task in the management of infective TPN complication.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>CVC related infections,Taurolidine,Parenteral nutrition,Lock solution</Keywords>
      <URLs>
        <Abstract>https://jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=8152&amp;title=Catheter-Related Infection (CRI) Treatment with Taurolidine - Citrate Lock Solution in Patients Undergoing Total Parenteral Nutrition</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References>Ball PA, Bethune K, Fox J, Ledger R, Barnett M. ‘’Particulate contamination in parenteral nutrition solutions: still a cause for concern?’’ Nutrition 2001; 17: 926-929.&#13;
&#13;
Bradshaw JH and Puntis JW. ‘’Taurolidine and catheter-related bloodstream infection: a systematic review of the literature’’. J Pediatr Gastroenterol Nutr 2008; 47: 179-186.&#13;
&#13;
Centers for Disease Control and Prevention. Guidelines for the prevention of intravascular catheter-related infections. MMWR Morb Mortal Wkly Rep 2002; 51: 1-29.&#13;
&#13;
Hollenbeak CS. The cost of catheter?related bloodstream infections: implications for the value of prevention. J Infus Nurs 2011; 34: 309-313.&#13;
&#13;
Johnston DA, Phillips G, Perry M, McAlpine H, Richards J, Pennington CR. ‘’Taurolidine for the prevention of parenteral nutrition related infection: antimicrobial activity and long-term use’’. Clin Nutr 1993; 12: 365-368.&#13;
&#13;
Joshi N and Mahajan N. Infection and diabetes. In: Pickup JC, Williams G, eds. Textbook of Diabetes. Oxford: Blackwell Science Ltd. 2003 ; 34: 1-16.&#13;
&#13;
Lebeaux D, Fernand;aacute;ndez-Hidalgo N, Chauhan A, Lee S, Ghigo JM, Almirante B, Beloin C. Management of infections related to totally implantable venous-access ports: challenges and perspectives. Lancet Infect Dis 2014b; 14: 146-159.&#13;
&#13;
Lebeaux D, Ghigo JM, Beloin C. Biofilm?related infections: bridging the gap between clinical management and undamental aspects of recalcitrance toward antibiotics. Microbiol Mol Biol Rev 2014a; 78: 510-443.&#13;
&#13;
Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, Oand;#39;Grady NP, Raad II, Rijnders BJ, Sherertz RJ, Warren DK. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clinical infectious diseases 2009; 49: 1-45.&#13;
&#13;
Van Den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345: 1359-1367.</References>
      </References>
    </Journal>
  </Article>
</ArticleSet>